[Microorganisms isolated in cases of pertussis-like syndrome]. / Microorganismos aislados en casos de síndrome pertusoide.

OBJECTIVE: To describe the etiologic study of the pertussis-like syndrome, not only as far as Bordetella genus is concerned but also regarding the causative role of other microorganisms for a 11-year period (1988-1998). METHODS: In all specimens from patients suffering from pertussis-like cough the presence of Bordetella spp., other bacteria, viruses, and mycoplasma was investigated. The analysed data included microbiological findings and epidemiologic issues (age, sex, hospital admission area, yearly distribution and seasonal period). RESULTS: A total of 1,063 specimens were investigated, most of them nasopharyngeal aspirates (910), corresponding to 905 patients; a positive culture was obtained form 56.9 of these patients. B. pertussis was isolated from 10.5% of patients. As for other bacteria, Haemophilus influenzae and Streptococcus pneumoniae were also isolated, in 16.9% and 15.8% of occasions, respectively. The respiratory syncitial virus was isolated from 10.7% of patients and other viruses in 9.4%. Among mycoplasma, Ureaplasma urealyticum predominated, with a recovery rate of 2.9%. The male/female ratio was 495/410; the ages of 67.2% of patients ranged from 0 to 6 months; a total of 689 (76.1%) required hospital admission. The recovery of B. pertussis and adenoviruses predominated during spring and summer months. In contrast, H. influenzae, S. pneumoniae and respiratory syncitial virus were recovered more frequently during winter months. CONCLUSIONS: Most patients with pertussis-like syndrome are children aged less than 6 months. The recovery percentages of B. pertussis and respiratory syncitial virus are identical and therefore we think that the investigation of their presence in this syndrome is fully warranted as well as the search for other microorganisms, since clinical symptoms are commonly non-specific among infants.

[Strains of ganciclovir-resistant cytomegalovirus]. / Cepas de citomegalovirus resistentes a ganciclovir.

BACKGROUND: In countries where the resistance of cytomegalovirus to ganciclovir has been studied, strains resistant to therapeutic doses of this drug have been isolated. When a change in treatment has been impossible the patient has shown bad clinical evolution. The aim of this study was to investigate the presence of these strains in our medium, observe whether the resistances appear in patients previously treated with ganciclovir and determine its implication in the evolution of cytomegalovirus infection. PATIENTS AND METHODS: One hundred twenty-three stains of cytomegalovirus, isolated during the period 1990-1998, corresponding to the following 94 patients were studied: 17 breast feeding children of healthy parents who were negative controls (sensitive strains), 43 organ transplant recipients, 29 AIDS patients, 2 with other immunodeficiencies and 3 children with intrauterine infection. Seventeen patients were studied due to the insidious course of the infection despite treatment. The remaining were random. The technique used was that of growth inhibition of the strains seeded on different gradients of ganciclovir: 0, 1, 5, 10 and 20 microM. The inoculate consisted in a cellular suspension evaluated according to the degree of viral growth. The strains presenting an inhibitory doses 50% (ID 50%) greater than 10 microM were considered as resistant. RESULTS: Eighty-two strains presented an ID 50% lower than 5 microM, 24 from 5 to 10 microM and in the 17 remaining strains, corresponding to 12 patients, the ID 50% was greater than 10 microM. The evolution of these latter 12 patients with strains considered to be resistant to ganciclovir was of death in 8. All were immunodepressed and with a history of having previously received ganciclovir. Another currently has a chronic evolution and the three remaining patients, who presented better immunity, became cured. All patients has a chronic evolution and the three remaining patients, who presented better immunity, became cured. All patients had undergone previous treatment with ganciclovir except two: one patient with Wegener disease treated with acyclovir 15 days before, and the other was an infant of an HIV positive mother who had received the drug. CONCLUSIONS: The presence of cytomegalovirus strains resistant to ganciclovir was confirmed in our patients. The previous use of ganciclovir and, in one case of acyclovir, appears to be implicated in the appearance of resistance. The evolution of the immunodepressed patients with infection by resistant strains was mortal except when their immunity was improved.

Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation.

To determine whether cytomegalovirus (CMV) disease is an independent risk factor for graft loss and death after orthotopic liver transplantation, we performed a 3-year follow-up study of 143 consecutive liver transplant recipients and six patients who underwent retransplantation. Thirty-seven patients (25%) had had CMV disease and were alive after treatment. Fifty-two deaths and eight graft losses occurred. The cumulative incidence of graft failure at 1 and 3 years of follow-up were 40% and 63%, respectively, for patients with CMV disease, compared with 22% and 33%, respectively, for those without CMV disease (P < .05, logrank test). Cumulative probabilities of survival for patients with and without CMV disease were 64% and 82%, respectively, at 1 year and 46% and 69%, respectively, after 3 years (P < .05, logrank test). Multivariate analysis with use of a time-dependent Cox model showed that previous CMV disease was an independent risk factor for graft loss at 1 and 3 years of follow-up (P = .04 and P = .007) and for patient survival (P = .04 and P = .01). Our results indicate that CMV disease is a significant independent risk factor for graft loss and patient survival after liver transplantation.

Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients.

Our objective in this study was to determine the efficacy of 2 grams a day of oral acyclovir administered for 16 weeks after transplantation for the prevention of cytomegalovirus (CMV) infection and disease in CMV-seropositive liver transplant recipients. Seventy-three adult liver transplant recipients, seropositive for CMV, were randomized to receive either 2 grams a day of oral acyclovir for 16 weeks after transplantation or no prophylaxis. The incidence of CMV disease was significantly lower in the acyclovir group (5%) than in the control group (27%; P < 0.05). By log-rank analysis, the differences in the probability of presenting CMV disease over the first 16 weeks and over the 1st year were also significant (P < 0.05). We conclude that 2 grams a day of oral acyclovir provides effective prophylaxis against CMV disease in CMV-seropositive liver transplant recipients.

[Digestive cytomegalovirus disease in AIDS patients]. / Enfermedad digestiva por citomegalovirus en pacientes con sida.

BACKGROUND: In this paper we study the digestive manifestations of cytomegalovirus (CMV) in AIDS patients. Also, we evaluate the antiviral treatment and the necessity of maintenance therapy. METHODS: Retrospective review of medical charts of all patients with AIDS and digestive CMV disease diagnosed and followed-up since 1983 to december 1993. RESULTS: Of 720 AIDS patients, 96 presented a CMV disease. Among them, 30 patients (31%) complained digestive manifestations. These were 26 males and 4 females, mean age: 37.4 y-old. Risk factors for HIV were: 13 homosex and 12 intravenous drug abusers. Average of time between AIDS diagnosis and digestive CMV disease: 13.4 months. Fourteen patients had esophagitis, 9 proctocolitis, 3 hepatitis, 3 pancreatitis, 2 gastric ulcerations, one small bowel disease and other an oral ulceration. Two patients had a concomitant CMV chorioretinitis. CD4 lymphocytes were below 0.05 x 10(9)/l in 29 patients. Twenty-four patients received antiviral treatment during the acute disease period, with a clinical curation rate of 60%. Seven patients received maintenance therapy and remained free of CMV disease until death. Eleven patients didn't received maintenance treatment. Of them, one patient presented a digestive relapse and two developed a CMV chorioretinitis. Mortality in the first month from diagnosis was 23% and the median of survival time for patients who cured and initial episode of digestive CMV disease was 208 days, wether or not the patient received maintenance therapy or not. CONCLUSIONS: One third of ours patients with AIDS and CMV infection have a digestive disease. This CMV digestive disease appears in patients with a severe immunosuppression. Acute phase mortality was 23%. The median survival was 7 months, independently or receiving maintenance treatment or not.

A simplified technique for determining the sensitivity of cytomegalovirus strains to ganciclovir.

A technique for determining the susceptibility to ganciclovir of cytomegalovirus (CMV) strains isolated in clinical samples is described. The inoculum was composed of a partially infected suspension of cells from a young positive culture (< 10 days), usually the first passage of the primary culture. The appropriate dilution of the cell suspension to provide a suitable inoculum was based on a previous study of five strains grown in different dilutions which provided a countable number of plaques and avoided titration of each of the isolated strains. Fifty-three strains were studied at three different dilutions. Five from patients on maintenance ganciclovir therapy with poor clinical response had a 50% inhibitory dose (ID50) between 21.46 and 13.35 microM and the remainder an ID50 between 2.31 and 10.5 microM, comparable to results obtained by other authors using susceptibility techniques with a sonicated inoculum. Three of these strains were studied by both methods using sonicated inoculum and cell suspension inoculum. The mean time which elapsed between seeding the specimen and obtaining sensitivity was 39.00 and 27.66 days, respectively. The technique reduces significantly the time involved since relatively young cultures can be studied and previous titration is not required.

[Incidence and etiology of viremia in 2,619 patients]. / Incidencia y etiología de la viremia en 2.619 pacientes.

BACKGROUND: Virus investigation, specially cytomegalovirus (CMV), in blood has increased such that the capacity of hospitalary laboratories is threatened with collapse. The causal agents of viremia are analyzed being correlated with the clinical symptoms and underlying disease to establish the selection criteria of patients for virologic study. METHODS: Two thousand six hundred nineteen patients suspected of having viral infection, fundamentally by CMV were studied over 6 years by 4,394 blood samples. Of these patients 1,646 were immunosuppressed, 824 were considered immunocompetent and this data was unknown in 149 patients. The leukocytes were separated using standardized techniques being seeded in cell cultures (human embryo lung fibroblasts). RESULTS: Three hundred forty-seven specimens corresponding to 242 patients were positive with isolation of the following pathogens: 327 strains of CMV, 4 enterovirus, 2 adenovirus, 1 herpes simplex virus, 1 varicella-zoster, another 5 unidentified cytopathic agents, 6 strains of toxoplasma and 1 Cryptococcus. With regard to the base disease, 302 positive samples to CMV pertained to 204 immunosuppressed patients: 103 (13.6% positives among the cases studied) AIDS or AIDS-related complex, 54 (21.3%) kidney transplant patients, 31 (24.8%) liver transplant patients, 2 (1.5%) lung transplant patients, and 2 (1.5%) bone marrow transplant patients. A non CMV microorganism was isolated in 13 samples from 12 immunosuppressed patients. Only 24 (2.5% of those studied) immunocompetent or with unknown immunity status had viremia by CMV, being detected in 25 samples. Non CMV cytopathic agents were isolated in another 7 samples from 6 patients. CONCLUSIONS: Analysis of blood cultures allows the isolation of cytomegalovirus and occasionally other unsuspected agents such as toxoplasma. This investigation is indicated in immunosuppressed patients but not in immunocompetent patients who present a febrile syndrome with no clinical suspicion of cytomegalovirus infection.

[Viral infections associated with intestinal invagination]. / Infecciones víricas asociadas a invaginación intestinal.

Intestinal invagination is rather frequently associated with local tumors, adenovirus infections, and occasionally with Yersinia enterocolitica. However, in many cases the etiology is not known. We have studied 88 children with intestinal invagination in whom cellular cultures of Hep 2 and pulmonary fibroblasts of human embryo have been inoculated with a fecal sample. The clinical reports have been reviewed retrospectively. In 19 patients (21.59%) we obtained an adenovirus and in 12 patients (13.63%) we isolated enteroviruses. These results have been compared with a control group of 1,059 children of a comparable age and during the same period of time who were admitted because diagnoses other than intestinal invagination. All controls where subjected to viral investigation in feces following the same procedure. In 71 of controls (6.7%) there were adenovirus in feces and in 74 cases (6.98%) the culture evidenced enteroviruses. Group differences for adenovirus were statistically significant (p = 0.00000172), whereas infections for enteroviruses reached a small significance (p = 0.03892). Among the 18 patients with intestinal invagination in whom the cultures were positive for adenoviruses, 10 presented a recent high airway infection. In contrast, this infection was only observed in 3 out of the 12 patients with culture positive to enteroviruses. The etiology of intestinal invagination in a large number of patients remains to be established. There are many pathogenic intestinal viruses that might cause intestinal invagination but they may be unable to grow into cellular cultures.